MLV & Co

MLV & Co initiated coverage on CyrusOne Inc. (NASDAQ: CONE) with a Hold rating. The target price for CyrusOne is set to $30. CyrusOne shares have gained 39.14% over the past 52 weeks, while the S&P 500 index has surged 15.12% in the same period. CyrusOne shares rose 3.34% to close at $28....

In a report published Thursday, MLV & Co analyst Jonathan Petersen initiated coverage on QTS Realty Trust (NYSE: QTS) with a Buy rating and $45.00 price target. In the report, MLV & Co noted, "We are initiating coverage of QTS with a BUY rating and a $45 price target. QTS has a knack for...

In a report published Thursday, MLV & Co analyst Jonathan Petersen initiated coverage on CyrusOne (NASDAQ: CONE) with a Hold rating and $30.00 price target. In the report, MLV & Co noted, "We are initiating on CONE with a HOLD rating and a $30 price target. CONE has a strong sales force,...

In a recent report, analysts at MLV & Co gave their monthly update on the lodging industry, including a list of their top picks in the space for investors. They believe that the lodging industry is beginning the late stages of a 10-year cycle similar to previous cycles in the 1990s and early...

In a report published Wednesday, MLV & Co analyst Arlinda Lee reiterated a Buy rating on Xencor (NASDAQ: XNCR), and raised the price target from $18.00 to $22.00. In the report, MLV & Co noted, “After reviewing IgG4-Related Disease (IgG4-RD) and XmAb5871 literature, we are more confident in...

In a report published Thursday, MLV & Co analyst Ryan Meliker downgraded the rating on Host Hotels and Resorts Inc (NYSE: HST) from Buy to Hold, but reiterated the $26.00 price target. In the report, MLV & Co noted, “Our HST downgrade to HOLD from BUY is driven by a current valuation that...

In a report published Thursday, MLV & Co analyst Arlinda Lee reiterated a Buy rating on Halozyme Therapeutics (NASDAQ: HALO), and raised the price target from $12.00 to $15.00. In the report, MLV & Co noted, “During its analyst day, HALO announced interim Ph2 PEGPH20 pancreatic cancer...

In a report published Wednesday, MLV & Co analyst George B. Zavoico reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX), and raised the price target from $21.00 to $25.00. In the report, MLV & Co noted, “We are raising our price target for Keryx Biopharmaceuticals, Inc. to $...

MLV & Co downgraded ARMOUR Residential REIT, Inc. (NYSE: ARR) from Buy to Hold and cut its price target from $4.50 to $4.00. Analyst Richard Eckert noted that the “lower rating is a product of the diminished upside potential represented by our new price target...and the smaller yield...

Analysts at MLV & Co initiated coverage on Ellington Financial LLC (NYSE: EFC) with a Hold rating. The target price for Ellington Financial is set to $21. Ellington Financial shares have dropped 8.99% over the past 52 weeks, while the S&P 500 index has gained 13.04% in the same period....

Analysts at MLV & Co initiated coverage on Halozyme Therapeutics, Inc. (NASDAQ: HALO) with a Buy rating. The target price for Halozyme Therapeutics is set to $12. Halozyme Therapeutics shares have dropped 42.48% over the past 52 weeks, while the S&P 500 index has gained 13.04% in the...

Ryan Meliker of MLV & Co initiated coverage of Ashford Inc. (NYSE: AINC) on Friday with a Buy rating and $110 price target. “Our Buy rating is driven by our confidence in management's ability to grow assets under management, which in turn will growth Ashford's earnings per...

Analysts at MLV & Co on Tuesday initiated coverage of Tenax Therapeutics Inc (NASDAQ: TENX) with a Buy rating and $7 price target. Tenax is a biotechnology company that focuses on localized oxygen delivery. Levosimendan Tenax is currently undergoing Phase III trials of its drug...